SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001346302-20-000061
Filing Date
2020-09-02
Accepted
2020-09-02 16:13:34
Documents
5
Period of Report
2020-09-02
Effectiveness Date
2020-09-02

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2020specialmeetingdefinit.htm DEF 14A 215825
2 definitiveproxycard-backop.jpg GRAPHIC 69149
3 definitiveproxycard-fronto.jpg GRAPHIC 164540
4 pauledicksignature1.jpg GRAPHIC 37016
5 xerislpharmrgba061.jpg GRAPHIC 124174
  Complete submission text file 0001346302-20-000061.txt   744275
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38536 | Film No.: 201157076
SIC: 2834 Pharmaceutical Preparations